Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Dragan Kalinić, Ranko Škrbić, Duško Vulić, Svjetlana Stoisavljević-Šatara, Nataša Stojaković, Miloš P Stojiljković, Vanda Marković-Peković, Ana Golić Jelić, Nataša Pilipović-Broćeta & Nevena Divac. (2023) Eleven-Year Trends in Lipid-Modifying Medicines Utilisation and Expenditure in a Low-Income Country: A Study from the Republic of Srpska, Bosnia and Herzegovina. ClinicoEconomics and Outcomes Research 15, pages 513-523.
Read now
Read now
Najmeh Ahangari, Majid Ghayour Mobarhan, Amirhossein Sahebkar & Alireza Pasdar. (2018) Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes. Annals of Medicine 50:4, pages 303-311.
Read now
Read now
Michel Farnier. (2017) Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review. Expert Review of Cardiovascular Therapy 15:12, pages 923-932.
Read now
Read now
Articles from other publishers (16)
Mingqi Ouyang, Chenyu Li, Die Hu, Daoquan Peng & Bilian Yu. (2022) Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition. Clinica Chimica Acta.
Crossref
Crossref
Chayakrit Krittanawong, Muzamil Khawaja, Robert S Rosenson, Christopher I. Amos, Vijay Nambi, Carl J Lavie & Salim S. Virani. (2022) Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy. Current Problems in Cardiology 47:7, pages 101043.
Crossref
Crossref
Victoria A. Korneva, Tatjana Yurjevna Kuznetsova & Ulrich Julius. (2021) Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases. Biomedicines 9:9, pages 1271.
Crossref
Crossref
M. Farnier. (2021) Nuevos hipolipidemiantes. EMC - Tratado de Medicina.
Crossref
Crossref
Lili Wang, Camilo Breton, Claude C. Warzecha, Peter Bell, Hanying Yan, Zhenning He, John White, Yanqing Zhu, Mingyao Li, Elizabeth L. Buza, Derek Jantz & James M. Wilson. (2021) Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9. Molecular Therapy 29:6, pages 2019-2029.
Crossref
Crossref
Donald J. AbrahamScott D. Edmondson, Duane A. Burnett & Harry R. DavisJrJr. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
36
.
Bruce A. Warden, Sergio Fazio & Michael D. Shapiro. (2020) The PCSK9 revolution: Current status, controversies, and future directions. Trends in Cardiovascular Medicine 30:3, pages 179-185.
Crossref
Crossref
Bruce A. Warden, Joshua R. Miles, Carlota Oleaga, Om P. Ganda, P. Barton Duell, Jonathan Q. Purnell, Michael D. Shapiro & Sergio Fazio. (2020) Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol. American Journal of Preventive Cardiology 1, pages 100012.
Crossref
Crossref
C Macchi, M Banach, A Corsini, CR Sirtori, N Ferri & M Ruscica. (2019) Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents. European Journal of Preventive Cardiology 26:9, pages 930-949.
Crossref
Crossref
Pierre Sabouret, Michel Farnier & Etienne Puymirat. (2019) Inhibiteurs de PCSK9 : quelle place dans la prise en charge actuelle des dyslipidémies ?. La Presse Médicale 48:3, pages 227-237.
Crossref
Crossref
Michel Farnier, G. Kees Hovingh, Gisle Langslet, Robert Dufour, Marie T. Baccara-Dinet, Chantal Din-Bell, Garen Manvelian & John R. Guyton. (2018) Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program. Atherosclerosis 278, pages 307-314.
Crossref
Crossref
Amy C. BurkeJacqueline S. DronRobert A. Hegele & Murray W. Huff. (2017) PCSK9: Regulation and Target for Drug Development for Dyslipidemia. Annual Review of Pharmacology and Toxicology 57:1, pages 223-244.
Crossref
Crossref
Michel Farnier. (2016) Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience. Current Opinion in Lipidology 27:6, pages 597-604.
Crossref
Crossref
Michel Farnier. (2016) Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk. Current Cardiology Reports 18:7.
Crossref
Crossref
Nabil G. Seidah. (2016) New developments in proprotein convertase subtilisin–kexin 9ʼs biology and clinical implications. Current Opinion in Lipidology 27:3, pages 274-281.
Crossref
Crossref
G. Klose. (2016) Einführung der PCSK9-InhibitorenIntroduction of PCSK9 inhibitors. Herz 41:4, pages 307-312.
Crossref
Crossref